KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Net Income (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Net Income for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 1328.95% to $1.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 billion, a 178.99% increase, with the full-year FY2025 number at $7.1 billion, up 178.99% from a year prior.
  • Net Income was $1.1 billion for Q4 2025 at Bristol Myers Squibb, down from $2.2 billion in the prior quarter.
  • In the past five years, Net Income ranged from a high of $2.5 billion in Q1 2025 to a low of -$11.9 billion in Q1 2024.
  • A 5-year average of $976.1 million and a median of $1.6 billion in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: surged 1426.25% in 2021, then plummeted 625.28% in 2024.
  • Bristol Myers Squibb's Net Income stood at $2.4 billion in 2021, then decreased by 14.63% to $2.0 billion in 2022, then decreased by 12.99% to $1.8 billion in 2023, then plummeted by 95.69% to $76.0 million in 2024, then skyrocketed by 1328.95% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Net Income are $1.1 billion (Q4 2025), $2.2 billion (Q3 2025), and $1.3 billion (Q2 2025).